Why the study?
CMS4 colorectal cancer is linked to therapy resistance and poor prognosis, but clinical diagnosis is hampered by locoregional and temporal variables, necessitating comprehensive diagnostic detection tools.
Does FAP expression and 68Ga-FAPI-PET imaging accurately identify the Consensus Molecular Subtype 4 (CMS4) in colorectal cancer?
Does FAP expression and 68Ga-FAPI-PET imaging accurately identify the Consensus Molecular Subtype 4 (CMS4) in colorectal cancer?
FAP expression accurately identifies the poor-prognosis CMS4 subtype in colorectal cancer, and 68Ga-FAPI-PET imaging can detect peritoneal metastases that are missed by conventional imaging.
No takes yet. Share an insight, caveat, or question.
FAP mRNA may identify high-risk CMS4 colorectal cancer; leaves open prospective validation of 68Ga-FAPI-PET for management.
Strating et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: